Increased expression of APAF-1 in low-risk myelodysplastic syndrome: a possible role in the pathophysiology of myelodysplasia

被引:4
|
作者
Benites, Bruno Deltreggia [1 ]
Traina, Fabiola [1 ]
Santos Duarte, Adriana da Silva [1 ]
Lorand-Metze, Irene Gyongyver H. [1 ]
Costa, Fernando Ferreira [1 ]
Saad, Sara Teresinha [1 ]
机构
[1] Univ Estadual Campinas, Dept Internal Med, Hematol & Hemotherapy Ctr, BR-13083970 Campinas, SP, Brazil
基金
巴西圣保罗研究基金会;
关键词
apoptotic protease-activating factor 1 (APAF-1); myelodysplastic syndrome; apoptosis; DEPENDENT APOPTOSIS; CELLS; PROGENITORS; MELANOMA; CANCER;
D O I
10.1111/j.1600-0609.2010.01429.x
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objectives: APAF-1 is a central component of the intrinsic pathway of apoptosis, where APAF-1 dysregulation results in the development of diverse human neoplasms. The aim of this study was to characterize the mRNA expression levels of APAF-1 transcripts in low-risk and high-risk MDS and to elucidate whether the expression levels of APAF-1 transcripts are modulated with increased apoptosis in CD34+ MDS cells undergoing erythroid differentiation. Methods: APAF-1 (NM_181861) expression was verified, by quantitative RT-PCR, in bone marrow aspirates from 33 patients with myelodysplastic syndromes (MDS), at the time of diagnosis, and in erythroid differentiation cultures from CD34+ from normal donors and patients with MDS. Results: APAF-1 expression was significantly higher in low-risk, compared to high-risk MDS, according to IPSS (P < 0.0001), FAB (P = 0.0265), and cytogenetic risk (P = 0.0134). Low-risk MDS-derived differentiated erythroid cells demonstrated an increased expression of APAF-1, compared with normal cells, accompanied by an augmented rate of apoptosis. Conclusions: Increased expression of APAF-1 in low-risk disease and its positive correlation with the apoptotic rate observed during the erythroblast differentiation of low-risk MDS cells may indicate that the modulation of APAF-1, at the transcriptional level, participates in the pathophysiology of MDS.
引用
收藏
页码:525 / 530
页数:6
相关论文
共 50 条
  • [21] The expression of P53 makes it possible to predict the evolution of patients with low-risk myelodysplasia with deletion 5q
    Eclache, Virginie
    HEMATOLOGIE, 2014, 20 (03): : 136 - 137
  • [22] Outcome of Patients With Low-Risk and Intermediate-1-Risk Myelodysplastic Syndrome After Hypomethylating Agent Failure
    Jabbour, Elias J.
    Garcia-Manero, Guillermo
    Strati, Paolo
    Mishra, Asmita
    Al Ali, Najla H.
    Padron, Eric
    Lancet, Jeffrey
    Kadia, Tapan
    Daver, Naval
    O'Brien, Susan
    Steensma, David P.
    Sekeres, Mikkael A.
    Gore, Steven D.
    Dezern, Amy
    Roboz, Gail J.
    List, Alan F.
    Kantarjian, Hagop M.
    Komrokji, Rami S.
    CANCER, 2015, 121 (06) : 876 - 882
  • [23] Mannuronic Acid in Low-Risk and Intermediate-1-Risk Myelodysplastic Syndromes
    Ghaderi, Afshin
    Nodehi, Sayyed Reza Safaee
    Bakhtiari, Tahereh
    Aslani, Mona
    Aghazadeh, Zahra
    Matsuo, Hidenori
    Rehm, Bernd H. A.
    Cuzzocrea, Salvatore
    Mirshafiey, Abbas
    JOURNAL OF CLINICAL PHARMACOLOGY, 2020, 60 (07): : 879 - 888
  • [24] Increased myeloid-derived suppressor cell activation in clonal cytopenia of undetermined significance and low-risk myelodysplastic syndrome
    Bentivegna, Sofia
    Come, Christophe
    Porse, Bo
    Andersen, Mads Hald
    Gronbaek, Kirsten
    BRITISH JOURNAL OF HAEMATOLOGY, 2024, 205 (03) : 1220 - 1224
  • [25] Impaired Expression of Focal Adhesion Kinase in Mesenchymal Stromal Cells from Low-Risk Myelodysplastic Syndrome Patients
    Wu, Yuenv
    Aanei, Carmen Mariana
    Kesr, Sanae
    Picot, Tiphanie
    Guyotat, Denis
    Catafal, Lydia Campos
    FRONTIERS IN ONCOLOGY, 2017, 7 : 164
  • [26] Killer Immunoglobulin-like Receptors (KIR) in Low-Risk Myelodysplastic Syndrome: Genotyping and Gene Expression Evaluation
    Coutinho, Diego
    Ali, Abdullah Mahmood
    Gualberto, Antonio
    Scholz, Catherine
    Bracken, Karen
    Jurcic, Joseph G.
    Raza, Azra
    BLOOD, 2017, 130
  • [27] Should Patients with Low-Risk Myelodysplastic Syndrome be Treated Earlier in the Course of Their Disease?
    Eric J. Feldman
    Current Hematologic Malignancy Reports, 2011, 6 : 1 - 2
  • [28] Should Patients with Low-Risk Myelodysplastic Syndrome be Treated Earlier in the Course of Their Disease?
    Feldman, Eric J.
    CURRENT HEMATOLOGIC MALIGNANCY REPORTS, 2011, 6 (01) : 1 - 2
  • [29] A MULTICENTRIC PROSPECTIVE PILOT STUDY ON FERROPTOSIS BIOMARKERS IN LOW-RISK MYELODYSPLASTIC SYNDROME
    D'avino, C.
    Pantaleo, A.
    Tsamesidis, I.
    Pilo, F.
    Reybier, K.
    Manca, A.
    Greco, M.
    Fozza, C.
    HAEMATOLOGICA, 2022, 107 : 63 - 64
  • [30] Successful Treatment of Hemophagocytic Lymphohistiocytosis Associated with Low-risk Myelodysplastic Syndrome by Azacitidine
    Daitoku, Shinya
    Aoyagi, Tomomi
    Takao, Shinichiro
    Tada, Seiya
    Kuroiwa, Mika
    INTERNAL MEDICINE, 2018, 57 (20) : 2995 - 2999